<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859492</url>
  </required_header>
  <id_info>
    <org_study_id>18-010602</org_study_id>
    <nct_id>NCT03859492</nct_id>
  </id_info>
  <brief_title>Screening CEDM in Intermediate and High-Risk Patient Populations</brief_title>
  <official_title>Screening Contrast Enhanced Mammography (CEDM) in Intermediate and High-Risk Patient Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to determine if Contrast Enhanced Digital Mammography
      (CEDM) can improve breast cancer detection and can be used as an additional screening method
      to the standard mammographic screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breast Cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Number of subjects diagnosed with breast cancer</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intermediate or high-risk breast cancer subjects</arm_group_label>
    <description>Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contrast Enhanced Digital Mammography</intervention_name>
    <description>High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image</description>
    <arm_group_label>Intermediate or high-risk breast cancer subjects</arm_group_label>
    <other_name>CEDM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potentially eligible patients who are scheduled for a mammogram will be prescreened based
        on their breast cancer risk level.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 35 and had a negative routine mammogram within 6 months.

          -  Qualifies as intermediate or high-risk (&gt;15% lifetime risk of breast cancer as defined
             by IBIS version 8).

        Exclusion Criteria:

          -  Known breast cancer

          -  Previously had negative MBI or MRI within 12 months of study

          -  Pregnant or lactating

          -  Contraindication to intravenous iodinated contrast

          -  Unable to understand or sign informed consent

          -  Self-reported signs or symptoms of breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhavika Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy L Lizzul, R.N.</last_name>
      <phone>480-342-1335</phone>
      <email>Lizzul.Annunziata@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brandee L. Colter</last_name>
      <phone>480-342-3988</phone>
      <email>Colter.Brandee@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patel Bhavika, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Bhavika Patel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

